---
title: "Ligand Pharmaceuticals Incorporated (LGND.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/LGND.US.md"
symbol: "LGND.US"
name: "Ligand Pharmaceuticals Incorporated"
industry: "Pharmaceuticals"
datetime: "2026-05-20T12:41:46.634Z"
locales:
  - [en](https://longbridge.com/en/quote/LGND.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/LGND.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/LGND.US.md)
---

# Ligand Pharmaceuticals Incorporated (LGND.US)

## Company Overview

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also provides Teriparatide injection product for osteoporosis; RYLAZE, a recombinant erwinia asparaginase for acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes in adults and children aged 8 years and older with Stage 2 T1D; and VAXNEUVANCE for the prevention of invasive disease caused by streptococcus pneumoniae serotypes. In addition, it offers Duavee for menopause; Frovatriptan to treat Neurology; FYCOMPA and SESQUIENT for CNS; MEKINIST for cardiology; Nexterone, a captisol-enabled formulation of amiodarone; VEKLURY, an antiviral treatment for COVID-19; and Viviant for osteoporosis.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |
| Website | [www.ligand.com](https://www.ligand.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:15.000Z

**Overall: B (0.31)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 15 / 189 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 51.24% |  |
| Net Profit YoY | 215.79% |  |
| P/B Ratio | 4.18 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4164131654.58 |  |
| Revenue | 274476000.00 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 17.13% | A |
| Profit Margin | 55.95% | A |
| Gross Margin | 89.52% | A |
| Revenue YoY | 51.24% | A |
| Net Profit YoY | 215.79% | A |
| Total Assets YoY | 69.21% | A |
| Net Assets YoY | 25.37% | A |
| Cash Flow Margin | 80.42% | C |
| OCF YoY | 51.24% | A |
| Turnover | 0.23 | D |
| Gearing Ratio | 34.91% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Ligand Pharmaceuticals Incorporated",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "51.24%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "215.79%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "4.18",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4164131654.58",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "274476000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "17.13%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "55.95%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "89.52%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "51.24%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "215.79%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "69.21%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "25.37%",
          "rating": "A"
        },
        {
          "name": "Cash Flow Margin",
          "value": "80.42%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "51.24%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.23",
          "rating": "D"
        },
        {
          "name": "Gearing Ratio",
          "value": "34.91%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 27.12 | 43/189 | 80.31 | 75.34 | 32.86 |
| PB | 4.18 | 139/189 | 4.27 | 3.98 | 3.30 |
| PS (TTM) | 15.17 | 123/189 | 17.24 | 15.43 | 14.38 |
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Cormedix (CRMD.US) | A | A | B | C | B | A |
| 02 | Eli Lilly (LLY.US) | A | A | B | D | B | B |
| 03 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | B | B |
| 04 | Roche (RHHBY.US) | A | B | B | D | B | B |
| 05 | AstraZeneca (AZN.US) | A | B | C | D | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-05-18T04:00:00.000Z

Total Analysts: **10**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 7 | 70% |
| Overweight | 2 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 207.78 |
| Highest Target | 330.00 |
| Lowest Target | 220.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/LGND.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/LGND.US/norm.md)
- [Related News](https://longbridge.com/en/quote/LGND.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/LGND.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**